Furthermore, evidence from research and clinical use of the drug class has led to the initiation of clinical trials with GLP‐1 RAs in other prominent aging‐related diseases, including chronic kidney disease (CKD) and Alzheimer's disease. Here, GCG is linked to chronic kidney disease.